| |
| |
SPOT ON
|
| |
Cardiotoxicity of cox-2-inhibitors and conventional NSAID: naproxen new standard
|
| |
| |
REVIEW
|
| |
Treatment of age-related macular degeneration (I)
|
| |
| |
THERAPY FORM A CRITICAL VIEWPOINT
|
| |
Once again: duration of therapy with clopidogrel (ISCOVER, PLAVIX) after drug-eluting stents
|
| |
| |
IN BRIEF
|
| |
Australia: price reduction for vaccine against human papilloma virus (HPV) GARDASIL
Olanzapine (ZYPREXA) and Eli Lilly: suppression of risk data
|
| |
| |
CURRENT ADR NETWORK REPORT
|
 |
Management of opiod-patches (e.g. Fentanyl (DUROGESIC)) fault-prone
|
| |
| |
SIDE EFFECTS
|
| |
US: market limitation of indications for telithromycine (KETEK) recommended
|
| |